Document:

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

Exhibit 10.22  

LICENSE AGREEMENT  

        This Non-Exclusive License Agreement (this "Agreement"), effective as of August 13, 2001 (the
"Effective Date"), is entered into by and between XOMA Ireland Limited, a company with limited liability organized under the laws of the Republic of
Ireland having offices at Shan- non Airport House, Shannon, County Clare, Ireland (with its Affiliates, "XOMA"), and Affymax, Inc., a
Delaware corporation having offices at 4001 Miranda Avenue, Palo Alto, California, 94304, U.S.A. ("Affymax"). 

BACKGROUND  

        A.    XOMA
is the owner or exclusive licensee of certain XOMA Patent Rights and Affymax wishes to acquire a non-exclusive license under the XOMA Patent Rights and
Know-How; and 

        B.    XOMA
is willing to grant Affymax non-exclusive licenses, on the terms and conditions set forth below, in order to permit Affymax to engage in certain research
activities. 

        NOW,
THEREFORE, in consideration of the promises and the mutual covenants herein-after recited, the parties agree as follows: 

ARTICLE 1

DEFINITIONS  

        In this Agreement, the following terms shall have the meanings set forth in this Article. 

        1.1   "Affiliate" means any corporation or other entity which is directly or indirectly controlling, controlled by or under
common control with a party hereto. For purposes of this Agreement, "control" (including, with correlative meanings, the terms
"controlled" and "controlling") means the possession, directly or indirectly, of the power to direct or
cause the direction of the management or policies of the subject corporation or other entity, whether through the ownership of voting securities, by agreement or otherwise. 

        1.2   "Affymax Collaborator" means any person or entity who, pursuant to a written agreement with Affymax meeting the
requirements of Section 2.4 of this Agreement on whose behalf Affymax engages in use of Licensed Materials to conduct Research. No person or entity shall be deemed to be an Affymax Collaborator
if such person or entity, either as of the date of its written agreement with Affymax or thereafter, is or was (a) infringing any XOMA Patent Rights and/or (b) engaged in the licensing,
manufacture, sale, offer for sale, import or export of phage display services, products or materials. 

 

        1.3   "Antibody Phage Display" means the use of Antibody Phage Display Materials. 

        1.4   "Antibody Phage Display Materials" means (i) any collection or library of polynucleotide sequences which encodes
at least one Immunoglobulin and which is contained in filamentous bacteriophage and/or bacteriophage or phagmid cloning vectors capable of propagation in bacteria; or (ii) any collection or
library of bacteriophage wherein an Immunoglobulin is expressed as a fusion protein comprising the Immunoglobulin and an outer surface polypeptide of a bacteriophage. 

        1.5   "Change in Control" means any transaction or series of transactions as a result of which any person or group (as defined
under the U.S. Securities Exchange Act of 1934, as amended) becomes, directly or indirectly, the beneficial owner of more than fifty percent (50%) of the total voting power of Affymax's equity
securities or otherwise gains control of Affymax. 

        1.6   "Confidential Information" means any proprietary or confidential information or material disclosed by a party to the
other party pursuant to this Agreement, which is (i) disclosed in tangible form hereunder and is designated thereon as "Confidential" at the time it is delivered to the receiving party, or
(ii) disclosed orally hereunder and identified as confidential or proprietary when disclosed and such disclosure of confidential information is confirmed in writing within thirty
(30) days by the disclosing party. 

        1.7   "Immunoglobulin" means any molecule that has an amino acid sequence by virtue of which it specifically interacts with an
antigen and wherein any chains of the molecule contain a functionally operating region of an antibody variable region including, without limitation, any naturally occurring or recombinant form of such
a molecule. 

        1.8   "Know-How" means unpatented and/or unpatentable technical information, including ideas, concepts, inventions,
discoveries, data, designs, formulas, specifications, procedures for experiments and tests and other protocols, results of experimentation and testing, fermentation and purification techniques, and
assay protocols owned by XOMA as of the Effective Date which may be necessary for the practice of the XOMA Patent Rights solely as contemplated hereunder and which XOMA has the right to license.
Know-How shall not include the XOMA Patent Rights. All Know-How shall be Confidential Information of XOMA. 

        1.9   "Licensed Materials" means solely those articles of manufacture, compositions of matter or apparatus which is made or
used under conditions, which, without a license, would con-stitute infringement of the XOMA Patent Rights. Excluded from the definition of Licensed Materials is any article of manufacture,
composition of matter or apparatus which, even if otherwise licensed hereunder, is made or used under conditions which infringe any claim of an issued patent owned or controlled by XOMA other than the
XOMA Patent Rights. 

        1.10 "Product" means any composition of matter or article of manufacture, including, without limitation any diagnostic,
prophylactic or therapeutic product, which was discovered or created by or arose out of or is related to use of Licensed Materials, and is made or sold under conditions which, if unlicensed, would
constitute infringement of the XOMA Patent Rights. 

[*]  = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

2

 

        1.11 "Research" means phage display, but specifically excludes Antibody Phage Display. 

        1.12 "Third Party" means any person or entity other than Affymax or XOMA. 

        1.13 "Valid Claim" means (i) a claim of an issued and unexpired patent included within the XOMA Patent Rights or
(ii) a claim of a pending patent application within the XOMA Patent Rights. 

        1.14 "XOMA Patent Rights" means the patent applications and patents listed on Exhibit A hereto and, solely to the
extent any Valid Claim would cover or be included in the license grants provided for herein, all divisions, continuations, continuations-in-part, and substitutions thereof; all
foreign patent applications corresponding to the preceding applications; and all U.S. and foreign patents issuing on any of the preceding applications, including extensions, reissues and
re-examinations. 

ARTICLE 2

LICENSE  

        2.1    Grant.    Subject to the other terms and conditions of this Agreement, XOMA hereby grants to Affymax, without
any right to sublicense, a worldwide, non-exclusive, non-transferable license under the XOMA Patent Rights and Know-How to, solely on its own behalf or on behalf of
an Affymax Collaborator, make and use Licensed Materials to conduct Research. 

        2.2    Covenant Not To Sue.    XOMA covenants that it will not initiate any claim of direct infringement against any
Affymax Collaborator solely to the extent reasonably necessary to permit Affymax's use of Licensed Materials for activities otherwise properly licensed in accordance with the provisions of this
Agreement. The covenant not to sue granted pursuant to this Section 2.2 is personal to each Affymax Collaborator, cannot be assigned or transferred and does not constitute a release or waiver
of past, present or future infringement of the XOMA Patent Rights by Affymax or any Third Party, including, without limitation, any Affymax Collaborator acting outside of the scope of the written
agreement with Affymax provided for in Section 2.4(a). Without limitation, the covenant not to sue granted pursuant to
this Section 2.2 does not extend or permit, except as otherwise provided for under this Agreement, the manufacture, import, export, sale or offer of sale of any Product, composition of matter
or article of manufacture infringing any Valid Claim of the XOMA Patent Rights. 

        2.3    No Implied Rights.    Only the rights and licenses granted pursuant to the express terms of this Agreement
shall be of any legal force or effect. No license or other rights shall be deemed to have been granted to Affymax other than as expressly provided for in this Agreement. Affymax, renounces and hereby
quitclaims any implied rights to licenses under the XOMA Patent Rights that may arise by operation of this Agreement or under applicable law. For the avoidance of doubt, the license grants pursuant to
Section 2.1 do not include, and expressly exclude, the following: 

[*]
= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

3

 

        (a)   any
right or license under the XOMA Patent Rights to sell, lease, license, transfer or dispose of the ownership or possession of any Licensed Materials or any Product; 

        (b)   any
right or license under the XOMA Patent Rights to commercialize any Licensed Materials or any Product; 

        (c)   any
right or license to engage in any activities on behalf of or in collaboration with any Third Party, other than an Affymax Collaborator; 

        (d)   any
right to release any Third Party, including an Affymax Collaborator, from any claim of infringement under the XOMA Patent Rights; and 

        (e)   to
engage in or cause any Third Party to engage in Antibody Phage Display or to use any Licensed Materials to identify, select, characterize, study or test an
Immunoglobulin. 

        2.4    Transfer Limitations.    (a) Affymax shall not make or use Licensed Materials on behalf of any Third
Party unless it is in receipt of a valid and enforceable written agreement pursuant to which that Third Party (i) represents and warrants that it has not, is not and will not infringe, directly
or indirectly, the XOMA Patent Rights; and (ii) acknowledges that it may not use any Product resulting from Affymax's use of Licensed Materials for any purpose other than for Research. 

        (b)   The
provisions of Section 2.4(a) shall not be applicable solely with respect to any Third Party (i) with whom XOMA enters into a license agreement prior to
the applicable activity by or with Affymax; and (ii) with respect to whom XOMA gives notice to Affymax that such license agreement meets the requirements of Section 2.4(a). 

        2.5    Ownership; Enforcement.    At all times XOMA will retain ownership of the XOMA Patent Rights and may use and
commercialize the XOMA Patent Rights itself or with any Third Party for any purpose whatsoever. XOMA retains the right, at its sole discretion, to enforce, maintain and otherwise protect the XOMA
Patent Rights. Within thirty (30) days of the Effective Date, and at all times thereafter during the term of this Agreement, Affymax shall give XOMA prompt notice in writing of all information
or facts in its possession which identify or are reasonably likely to lead to the identification of any unauthorized use of the XOMA Patent Rights, including without limitation the conduct of any
activities outside of the scope of the license grants pursuant to Section 2.1. Affymax, at XOMA's expense, shall cooperate with XOMA's reasonable written demands to Affymax with respect to any
actions XOMA may choose to take related to the enforcement, maintenance or protection of the XOMA Patent Rights. 

[*]
= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

4

 

        2.6    Reports, Inspection and Audits.    (a) Within thirty (30) days of the end of each
calen-dar quarter, Affymax shall deliver to XOMA a written report which (i) specifies the name, address and contact person for each and every Affymax Collaborator;
(ii) describes in reasonable detail the current status and scope of any activities which involve the use of Licensed Materials; and (iii) identifies all Products. 

        (b)   Affymax
shall maintain original records fully and properly reflecting those activities to be reported to XOMA pursuant to Section 2.6(a) (together with the
written materials required by Section 2.4(a) the "Records"), in sufficient detail and in good scientific manner appropriate for patent,
regulatory and manufacturing purposes. XOMA shall have the right to arrange for its auditors, and contractors to visit Affymax at its offices and laboratories and other facilities, wherever located,
concerning the subject matter of this Agreement, during normal business hours on reasonable notice, with the right to copy all Records. 

ARTICLE 3

PAYMENTS  

        3.1    Technology Access Fee.    In consideration for XOMA's execution of this Agree-ment, Affymax shall
pay XOMA on the Effective Date a non-refundable technology access fee of [ *  ] United States Dollars [ *
 ]. 

        3.2    Annual Maintenance Fee.    On July 1 of each year from  [ * ] during the
term hereof, Affymax shall pay XOMA an annual maintenance fee
of [ * ] United States Dollars     [ * ].

        3.3    Collaborator Access Fee.    No activity shall be undertaken on behalf of any Affymax Collaborator until payment
by Affymax of an initial fee of [ * ] United States Dollars  [ * ] (as to each Affymax Collaborator, a "Collaboration
Fee") for such collaboration. For so long as Affymax is undertaking any activity on behalf of such Affymax Collaborator, on each successive annual anniversary of the payment of
the Collaboration Fee, Affymax shall pay an additional Collaboration Fee. 

        3.4    Payments.    All payments due hereunder shall be paid by wire transfer in United States Dollars in immediately
available funds to an account designated by XOMA. 

ARTICLE 4

CONFIDENTIALITY  

[*]  = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

5

 

        4.1    Confidential Information.    Except as expressly provided herein, the parties agree that, for the term of this
Agreement and for five (5) years thereafter, the receiving party shall keep completely confidential and shall not publish or otherwise disclose and shall not use for any purpose except for the
purposes contemplated by this Agreement any Confidential Information furnished to it by the disclosing party hereto, except to the extent that it can be established by the re-ceiving party
by written proof that such Confidential Information: 

        (a)   was
already known to the receiving party, other than under an obligation of confidentiality, at the time of disclosure; 

        (b)   was
generally available to the public or otherwise part of the public domain at the time of its disclosure to the receiving party; 

        (c)   became
generally available to the public or otherwise part of the public domain after its disclosure other than through any act or omission of the receiving party in
breach of this Agreement; or 

        (d)   was
subsequently lawfully disclosed to the receiving party by a person other than a party hereto. 

        4.2    Permitted Use and Disclosures.    Each party hereto may use or disclose information disclosed to it by the
other party to the extent such use or disclosure is reasonably necessary in complying with applicable law or government regulations or conducting clinical trials. 

        4.3    Confidential Terms.    Except as expressly provided herein, Affymax agrees not to disclose any terms of this
Agreement to any Third Party without the consent of XOMA; provided, that disclosures may be made as required by securities or other applicable laws, or
to a party's ac-countants, attorneys and other professional advisors. 

        4.4    Agreement Announcement.    The parties hereby agree that the consummation of this Agreement shall be deemed to
be in the public domain and its existence (but not specific terms) may be announced or otherwise referred to by the parties as they deem appropriate. Notwithstanding the foregoing, prior to execution
of this Agreement, the parties shall agree upon language that can be used to describe the terms of this transaction, and each party may disclose such language, as modified by mutual agreement from
time to time, without the other party's consent. 

ARTICLE 5

REPRESENTATIONS AND WARRANTIES  

        5.1    Representations and Warranties.    Affymax represents and warrants to XOMA that: (i) Affymax has the
legal right, authority and power to enter into this Agreement; (ii) this Agreement shall constitute a valid and binding obligation of Affymax enforceable in accordance with its terms;
(iii) the performance of obligations under this Agreement by Affymax will not result in a breach of any agreements, contracts or other arrangements to which it is a party; and
(iv) Affymax has no notice or other knowledge of any infringement of the XOMA Patent Rights by any Third Party. 

[*]
= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

6

 

        5.2    Disclaimer.    Nothing in this Agreement is or shall be construed as: 

        (a)   A
warranty or representation by XOMA as to the validity or scope of any claim or patent within the XOMA Patent Rights; 

        (b)   A
warranty or representation that anything made, used, sold, or otherwise disposed of under any license granted in this Agreement is or will be free from infringement of
any patent rights or other intellectual property right of any Third Party; 

        (c)   An
obligation to bring or prosecute actions or suits against Third Parties for infringement of any of the XOMA Patent Rights; 

        (d)   Granting
by implication, estoppel, or otherwise any licenses or rights under patents or other rights of XOMA or Third Parties, regardless of whether such patents or
other rights are dominant or subordinate to any patent within the XOMA Patent Rights. 

        5.3    No Other Warranties.    XOMA MAKES NO WARRANTIES WITH RESPECT TO THE XOMA PATENT RIGHTS, EXPRESS OR IMPLIED,
EITHER IN FACT OR BY OPERATION OF LAW, BY STATUTE OR OTHERWISE, AND XOMA SPECIFICALLY DISCLAIMS ANY EXPRESS OR IMPLIED WARRANTY OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, VALIDITY OF THE
XOMA PATENT RIGHTS OR NON-INFRINGEMENT OF THE INTELLECTUAL PROPERTY RIGHTS OF ANY THIRD PARTY. 

ARTICLE 6

INDEMNIFICATION  

        Affymax agrees to indemnify, defend and hold XOMA and its Affiliates, directors, officers, employees and agents harmless from and against any and all liabilities,
losses and expenses (including, without limitation, attorneys and professional fees and other costs of litigation), resulting from any claims, demands or causes of action by any party other than
Affymax (each, a "Liability") arising out of (i) the possession, manufacture, use, sale or other disposition of either Licensed Materials or any
product of the practice of any method within the scope of the XOMA Patent Rights or Know-How by Affymax, whether based on breach of warranty, negligence, product liability or otherwise,
(ii) the exercise of any right granted to Affymax pursuant to this Agreement or (iii) any breach of this Agreement by Affymax, except to the extent, in each case, that such Liability is
caused by the willful misconduct of XOMA. 

[*]  = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

7

 
ARTICLE 7

TERM AND TERMINATION  

        7.1    Term.    Subject to Section 7.5, the term of this Agreement will commence on the Effective Date and
remain in full force and effect until the expiration of the last patent within the XOMA Patent Rights, unless earlier terminated for cause pursuant to Section 7.2. 

        7.2    Termination for Cause.    Either party may terminate this Agreement (i) upon sixty (60) days
written notice or (ii) in the event the other party has materially breached this Agreement or has breached or defaulted in the performance of any of its obligations set forth in Articles 2, 3,
4, 5 and 6 or in Sections 7.4, 8.2, 8.7 and 8.8 or infringed any patent not otherwise licensed hereunder and such breach, default or infringement has continued for thirty (30) days after
written notice thereof was provided to the breaching party by the nonbreaching party. Any termination for cause shall become effective on the first day immediately following such thirty
(30) day period unless the breaching party has cured any such breach, default or infringement prior to the expiration of such period. Notwithstanding the above, in the case of a failure to pay
any amount due hereunder the period for cure of any such default following notice thereof shall be five (5) days and, unless payment is made within such period, the termination shall become
effective at the end of such period. 

        7.3    Termination for Insolvency.    If voluntary or involuntary proceedings by or against a party are instituted in
bankruptcy under any insolvency law, or a receiver or custodian is appointed for such party, or proceedings are instituted by or against such party for corporate reorganization or the dissolution of
such party, which proceedings, if involuntary, shall not have been dismissed within sixty (60) days after the date of filing, or if such party makes an assignment for the benefit of creditors,
or substantially all of the assets of such party are seized or attached and not released within sixty (60) days thereafter, the other party may immediately terminate this Agreement effective
upon notice of such termination. 

        7.4    Contested Validity.    If Affymax, an Affymax Collaborator or any person or entity controlled by any of the
foregoing contests or assists another in contesting the validity of any of the XOMA Patent Rights licensed hereunder, XOMA shall have the right to terminate this Agreement. 

        7.5    Effect of Termination.    (a) Termination of this Agreement shall not release any party hereto from any
liability which, at the time of such termination, has already accrued to the other party or which is attributable to a period prior to such termination nor preclude either party from pursuing any
rights and remedies it may have hereunder or at law or in equity with respect to any breach of this Agreement. It is understood and agreed that monetary damages may not be a sufficient remedy for any
breach of this Agreement and that the non-breaching party may be entitled to injunctive relief as a remedy for any such breach. Such remedy shall not be deemed to be the exclusive remedy
for any such breach of this Agreement, but shall be in addition to all other remedies available at law or in equity. 

[*]
= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

8

 

        (b)   Upon
any termination of this Agreement, Affymax and XOMA shall promptly return to the other party all Confidential Information received from the other party (except that
each party may retain one copy for its files solely for the purpose of determining its rights and obligations hereunder). 

        (c)   All
licenses granted hereunder shall terminate upon the termination of this Agreement. 

        7.6    Survival.    Sections 2.5, 2.6(b), 7.5 and 7.6, and Articles 4, 5, 6 and 8 of this Agreement shall survive any
termination of this Agreement. 

ARTICLE 8

MISCELLANEOUS PROVISIONS  

        8.1    Governing Laws; Venue.    This Agreement and any dispute, including without limitation any arbitration, arising
from the performance or breach hereof shall be governed by and construed and enforced in accordance with the laws of the state of California, without reference to conflicts of laws principles. The
exclusive venue of any dispute arising out of or in connection with the performance of breach of this Agreement shall be the California state courts or U.S. district court located in San Francisco,
California, and the parties hereby consent to the personal jurisdiction of such courts and waive any objection that any such court would be an inconvenient forum. 

        8.2    Assignment.    Affymax may not transfer or assign this Agreement, or any of Affymax's rights hereunder without
the prior written consent of XOMA, which consent will not be unreasonably withheld; provided, that for purposes of this Agreement, a Change in Control
shall be deemed to be a transfer or assignment. Any such attempted transfer or assignment in violation of this Section 8.2 shall be void;  provided, that in the event of a Change in Control not
otherwise consented to in writing by XOMA,
XOMA shall have the option in its discretion of terminating this Agreement or continuing Affymax's (or its successor's) obligations hereunder. XOMA may assign this Agreement or its rights hereunder.
This Agreement shall be binding upon and inure to the benefit of the parties and their permitted successors and assigns. 

        8.3    Waiver.    No waiver of any rights shall be effective unless consented to in writing by the party to be charged
and the waiver of any breach or default shall not constitute a waiver of any other right hereunder or any subsequent breach or default. 

[*]  = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

9

 

        8.4    Severability.    In the event that any provisions of this Agreement are determined to be invalid or
unenforceable by a court of competent jurisdiction, the remainder of the Agreement shall remain in full force and effect without said provision. 

        8.5    Notices.    All notices, requests and other communications hereunder shall be in writing and shall be delivered
or sent in each case to the respective address specified below, or such other address as may be specified in writing to the other party hereto, and shall be effective on receipt: 

	 	 	Affymax:	 	Affymax, Inc.

4001 Miranda Avenue

Palo Alto, California 94304, U.S.A.

Attn: Legal Department
	
 with a copy (which shall not constitute notice to):
	
 	
 	

 	
 	

Brobeck, Phleger & Harrison LLP

12390 El Camino Real

San Diego, CA 92130

Attn: Vickie G. Norton, Esq.
	
 	
 	

XOMA:	
 	

XOMA Ireland Limited

Shannon Airport House

Shannon, County Clare

Ireland

Attn: Company Secretary
	
 with a copy (which shall not constitute notice) to:
	
 	
 	

 	
 	

XOMA (US) LLC

2910 Seventh Street

Berkeley, CA 94710

USA

Attn: Company Secretary

        8.6    Independent Contractors.    Both parties are independent contractors under this Agreement. Nothing contained in
this Agreement is intended nor is to be construed so as to constitute XOMA or Affymax as partners or joint venturers with respect to this Agreement. Except as expressly provided herein, neither party
shall have any express or implied right or authority to assume or create any obligations on behalf of or in the name of the other party or to bind the other party to any other contract, agreement, or
undertaking with any third party. 

[*]  = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

10

 

        8.7    Compliance with Laws.    In exercising their rights under this license, the parties shall comply in all
material respects with the requirements of any and all applicable laws, regulations, rules and orders of any governmental body having jurisdiction over the exercise of rights under this Agreement.
Affymax shall be responsible, at its expense, for making any required registrations or filings with respect to this Agreement and obtaining any necessary governmental approvals with respect hereto. 

        8.8    Use of Name.    Neither party shall use the name or trademarks of the other party, except to the extent that a
party is permitted to use the Confidential Information of the other party pursuant to Article 4, without the prior written consent of such other party. 

        8.9    Further Actions.    Each party agrees to execute, acknowledge and deliver such further instruments, and do such
other acts, as may be necessary and appropriate in order to carry out the purposes and intent of this Agreement. 

        8.10    Entire Agreement; Amendment.    This Agreement constitutes the entire and exclusive Agreement between the
parties with respect to the subject matter hereof and supersedes and cancels all previous discussions, agreements, commitments and writings in respect thereof, including without limitation the
Predecessor Agreement. No amendment or addition to this Agreement shall be effective unless reduced to writing and executed by the authorized representatives of the parties. 

        IN
WITNESS WHEREOF, XOMA and Affymax have executed this Agreement in duplicate originals by duly authorized officers. 

	AFFYMAX, INC.	 	XOMA IRELAND LIMITED
	

By:	
 	

/s/  LORI RAFIELD      
 Lori F. Rafield

Co-President	
 	

By:	
 	

/s/  ALAN KANE      
 Alan Kane, Director

duly authorized for and on behalf of

XOMA Ireland Limited in the

presence of:
	

 	
 	

 	
 	

 	
 	

/s/  KEJIN DONODA      

	

 	
 	

Date: 10/29/01
	
 	

 	
 	

Date: 1/11/01

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND
FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

11

 
Exhibit A  

	Title:	 	AraB Promoters and Method of Producing Polypeptides, Including Cecropins, by Microbiological Techniques
	Inventors:	 	Lai, Lee, Lin, Ray, Wilcox

        Based
on PCT/US86/00131, which is a continuation-in-part of U.S. Serial No. 06/695,309 filed January 28, 1985 (abandoned). 

	COUNTRY
 
	 	SERIAL NO.
 
	 	PATENT NO.
 

	Austria	 	EP 86900983.7	 	EP/0211047
	Belgium	 	EP 86900983.7	 	EP/0211047
	Europe	 	EP 86900983.7	 	EP/0211047
	Finland	 	863891	 	94774
	France	 	EP 86900983.7	 	EP/0211047
	Germany	 	EP 86900983.7	 	P3689598.9-08
	Italy	 	EP 86900983.7	 	EP/0211047
	Japan	 	500818/86	 	2095930
	Japan	 	094753/94	 	2121896
	Luxembourg	 	EP 86900983.7	 	EP/0211047
	Netherlands	 	EP 86900983.7	 	EP/0211047
	Norway	 	863806	 	175870
	Sweden	 	EP 86900983.7	 	EP/0211047
	Switzerland/Liechtenstein	 	EP 86900983.7	 	EP/0211047
	United Kingdom	 	EP 86900983.7	 	EP/0211047
	*United States	 	06/695,309	 	 
	*United States	 	06/797,472	 	 
	United States	 	07/474,304	 	5,028,530

	*
	Cases
abandoned in favor of a continuing application. 

[*]
= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

12[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

Exhibit 10.23  

Dr. Shawn
Lee, Ph.D.

Chief Operating Officer

American Peptide Company

777 Evelyn Avenue

Sunnyvale, CA 94086 

Re:
Letter Agreement (the "Letter Agreement") between Affymax, Inc., with registered offices at 4001 Miranda Avenue, Palo Alto, CA, 94304, USA, ("Affymax"), and American Peptide
Company, Inc., a California corporation with registered offices at 777 Evelyn Avenue, Sunnyvale, California ("APC"). 

9
October, 2003 

Dear
Dr. Lee: 

        As
you know, Affymax and APC have agreed to negotiate with respect to a process development and supply agreement in which APC will manufacture and supply Affymax with Affymax's
requirements for Affymax's proprietary peptide product Hematide through phase II clinical trials (the "Development and Supply Agreement"). To meet the tight timelines required for APC to deliver the
first samples of such peptide drug substance to Affymax, APC will need to complete the initial feasibility and process development work before the parties expect to complete negotiating the defmitive
Development and Supply Agreement; however, nothing in this Letter Agreement shall obligate either party to agree and enter into a definitive Development and Supply Agreement. Thus, to allow APC to
begin process development work and deliver certain amounts of peptide Drug Substance while the parties negotiate the definitive Development and Supply Agreement, we have prepared this Letter
Agreement, which confirms our recent discussions and understandings. We agree as follows: 

1.    Definitions. Capitalized terms used in this Letter Agreement (other than the headings of the Paragraphs), whether used in the singular
or plural, shall have the meaning set forth below, or, if not listed below, the meaning as designated in the text of this Letter Agreement. 

        "cGMP"
shall mean then-current good manufacturing practices required by: (i) by the provisions of 21 C.F.R., parts 210 and 211 and all applicable rules, regulations,
orders and guidances (as the same may from time to time be amended); and (ii) the provisions of Chapter II of EC Commission Directive 91\356\EEC together with ICH Guideline UCH Q7A (Good
Manufacturing Practice for Active Pharmaceutical Ingredients, November 16, 2000). 

        "CMC
Documentation" shall mean the documentation of analytical methods and validation procedures related to the manufacture of the Drug Substance that is prepared in accordance with the
Guidelines for Industry, Analytical Methods and Validation Procedures (Chemistry, Manufacturing and Controls documentation), as published by the Center for Drug Evaluation and 

Research
and the Center for Biologics Evaluation and Research in August 2000, and any finalized or successor guidelines thereto. 

        "Drug
Substance" shall mean Affymax's EPO mimetic drug Drug Substance identified as Hematide and further defined in the specifications as  [*] ([*])."Drug Master
File" or "DMF" shall mean
appropriate DMF's, as defined by FDA's Guideline for Drug Master Files, September 1989 (http://www.fda.gov/cder/guidance/dmfhtm) and EMEA (http://www.emea.eu.int/pdfs/human/qwp/013402.pdf)
appropriate to support Affymax's Investigational New Drug Application ("IND") for Drug Substance. 

        "Control"
or "Controlled" shall mean with respect to any intellectual property, that a party owns or has a license to such intellectual property and has the ability to grant to the other
party access, a license or a sublicense (as applicable) to such intellectual property as provided for herein without violating the terms of any agreement or other arrangements with any third party
existing at the time such party would be first required hereunder to grant the other party such access, license or sublicense. 

        "Development
Phase" shall have the meaning set forth in Paragraph 2. 

        "Effective
Date" shall mean the date on which this Letter Agreement is signed by the representative of APC below. 

        "Feasibility
Phase" shall have the meaning set forth in Paragraph 2. 

        "Interim
Specifications" shall mean the specifications for Drug Substance as described in the quotation provided by APC in a letter of 17 July 2003 identified as Quotation Number
031707-G2 and attached as Exhibit A. 

        "Know-How"
shall mean all technical, scientific and other know-how, information, trade secrets, knowledge, ideas, inventions, concepts, formulae, procedures,
methods, processes, protocols, techniques, materials and results of experimentation and testing, including without limitation, samples, data, and results (whether or not patentable), in each case that
are developed or made by a party, either solely or jointly with the other party, in the course of performance of its obligations under this Letter Agreement. Know-How expressly excludes
any Patents. 

        "Patents"
shall mean: (i) all U.S. and non-U.S. patent applications; (ii) all provisionals, converted provisionals, divisionals, continuations and
continuations-in-part thereto; and (iii) all patents, issuing from the foregoing in (i) and (ii), including without limitation all extensions,
re-examinations, reissues, substitutions and inventors certificates; in each case that are conceived, reduced to practice, made or developed by a party, either solely or jointly with the
other party, in the course of performance of its obligations under this Letter Agreement. 

2.    Project; Committed Resources; Schedule. Affymax and APC are entering into a development and manufacturing relationship (the "Project")
in which APC shall produce and provide Affymax's requirements for initial clinical supplies of Drug Substance in full compliance with certain specifications to be determined by the parties in the
course of the Project and as shown in Exhibit B, pages 1 and 2 (the "Clinical Specifications") and cGMP, all as further described below. APC shall commit to the Project appropriate personnel,
including without 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

limitation
experts in technical development, manufacturing, operations, quality control, quality assurance and regulatory affairs. Affymax shall commit such of its personnel or its agents with
appropriate expertise to provide reasonable monitoring and technical consultation for the Project, as appropriate and agreed upon in writing by the parties. APC recognizes the importance of timely
execution of the Project and accordingly shall give priority to the Project, assign adequate staffing and other resources and use all diligent, commercially reasonable efforts to maximize the
potential of achieving successful completion of the Project according to the following schedule: 

        APC
shall complete the set-up of the process for the production of at least one hundred (100) grams of cGMP-grade Drug Substance that is suitable for human
clinical use and meeting the Clinical Specifications (the "Early-Stage Clinical Drug Substance"). The Early-Stage Clinical Drug Substance shall be delivered to Affymax or Affymax's designee(s)
according to instructions from Affymax. APC shall ship to Affymax or Affymax's designee approximately [*] as soon as possible
following synthesis of the [*] and prior to release of Early Stage Clinical Drug Substance. APC shall release at least
seventy-five (75) grams and any excess up to one hundred (100) grams total and ship approximately thirty (30) grams (or as otherwise specified by Affymax) of the first
batch or lot of Early-Stage Clinical Drug Substance by November 28, 2003 and retain the remainder under GMP conditions suitable for subsequent shipment(s) for clinical use in humans. APC shall
ship subsequent portions of the initial batch of Early-Stage Clinical Drug Substance within five (5) business days following receipt of written instructions from Affymax; if a shipment is
delayed in excess of five (5) business days, APC shall pay to Affymax [*] U.S. Dollars for each additional business day
of delay unless such delay can be shown to Affymax's satisfaction to be due to a valid and reasonable cause. Upon APC's release and delivery of the first batch of Early-Stage Clinical Drug Substance
to Affymax and at Affymax's request, APC shall also provide to Affymax at such time a report describing the preparation of scale up, analytical methods, stability testing, validation and CMC
Documentation (the "Development Phase Report"). The Development Phase Report shall be delivered to Affymax within 10 days of shipment of the first batch of Early-Stage Clinical Drug Substance. 

        APC
shall prepare and deliver to Affymax within the time frame set forth on Exhibit B, and if requested by Affymax, submit to the appropriate US and foreign regulatory
authorities, a drug master file ("DMF") for APC's manufacture of Drug Substance within 90 days of the initial release and shipment of Early Stage Clinical Drug Substance. APC shall also provide
Affymax with a letter of access allowing Affymax and its sublicencee(s) to reference the DMF in Affymax's regulatory filings. The DMF shall be in compliance with requirements for drug master file
submissions to the United States Food and Drug Administration (the "FDA"). The parties acknowledge that the stability data used or included in the DMF submission shall cover only such period as is
available to APC at the time it is prepared. The parties shall consult and co-operate closely with each other in relation to the preparation of the DMF and any subsequent regulatory
filings and inspections related thereto. A copy of any subsequent regulatory filings shall be provided to Affymax at the time of submission to the regulatory authorities. 

3.    Cost. The cost to Affymax shall be as specified in Section (A) of Quotation 031707-G2 attached as Appendix A
for [*]. APC will QC release an entire one
hundred (100) gram single batch of Early-Stage Drug Substance, of which approximately 30 grams or portion thereof (as will be specified by Affymax) shall be delivered to Affymax or Affymax's
designee and the 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

remainder
of the batch retained by APC and delivered according to Affymax's subsequent instructions. The total cost of the Development Phase to Affymax shall be payable as follows: Affymax shall pay
APC [*] U.S. Dollars within thirty (30) days after the release of the initial one hundred (100) gram batch and
Affymax's receipt of the initial approximately thirty (30) gram shipment of Early-Stage Clinical Drug Substance-conforming to specifications, however, the net initial payment shall be a net sum
of [*] U.S. Dollars in view of the non-refundable pre-payment of  [*] U.S. Dollars paid by Affymax to APC pursuant to the letter agreement between the
parties dated July 29, 2003 and
additional non-refundable pre-payment of [*] U.S. Dollars pursuant to the letter memorandum of
September 15, 2003, and which pre-payments shall be credited against the payment due; APC may invoice Affymax upon release and shipment of at least approximately thirty
(30) grams of an at least one hundred (100) gram batch or lot of Early-Stage Clinical Drug Substance conforming to specifications, including receipt of all relevant documentation and
Certificate(s) of Analysis. APC will deliver and invoice the Development Phase Report including the CMC Documentation and a copy of the DMF and related information and, upon receipt and acceptance by
Affymax, Affymax shall pay [*] U.S. Dollars for said Development Phase Report and  [*] U.S. Dollars for said DMF, which APC may invoice upon submission of
the DMF to the Food and Drug Administration and, if so
instructed by Affymax, APC shall also submit or cause to be filed a DMF with the EMEA (European Medicines Evaluation Agency) and may invoice Affymax for an additional  [*] U.S. Dollars upon submission.
If requested by Affymax, APC shall reasonably undertake to file DMF or similarly required
documentation in other foreign regulatory authority offices and shall be reimbursed for reasonable costs plus an amount to be determined by the parties according to industry standards and not to
exceed [*] per submission. Failure of APC to deliver the CMC Documentation and file the DMF with the US Food and Drug
Administration within 90 days following the initial shipment of Early-Stage Clinical Drug Substance shall result in the payment due from Affymax to APC being reduced by  [*] per business day for
each day of delay commencing upon the 91st day following the date of initial shipment of the batch of
Early-Stage Clinical Drug Substance. At Affymax's discretion and with the proviso that an analytical testing method will be identified by Affymax and acquired and implemented by APC prior to study
initiation, APC will conduct a two-year stability study per ICH guidelines on the Early-Stage Clinical Drug Substance which would be fully prepaid by Affymax in a total amount of  [*] U.S. Dollars upon
initialization of the test protocol. Any additional analytical and process development activities to be
performed by APC, if any, will be at reasonable cost
according to industry standards, shall be determined by the parties and shall be agreed upon in writing signed by authorized representatives. All amounts due by one party hereunder shall be paid in
dollars by wire transfer in immediately available funds to an account designated by the receiving party. 

4.    Intellectual Property; Licenses. Except to the extent provided in this Letter Agreement, neither Affymax nor APC grants any right, title
or interest in any of its information, inventions, discoveries, processes, methods, compositions, formulae, procedures, protocols, improvements, techniques, data and intellectual property of any kind,
whether or not copyrightable or patentable, that exist as of the Effective Date or are developed during the term of this Letter Agreement by a party independently of its performance pursuant to this
Letter Agreement ("Non-Project Intellectual Property") to the other party and made independently of any work based on information disclosed under confidentiality by the other party. 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

        During
the term of this Letter Agreement, each party shall disclose promptly to the other party in writing all Patents and Know-How. The parties shall jointly own all Patents
and Know-How that relate solely to general peptide synthesis technology ("Peptide Intellectual Property"), and each party hereby assigns to the other party any of such first party's right,
title and interest in all Peptide Intellectual Property necessary to provide the other party with an one-half (1/2) undivided interest in and to such Peptide Intellectual
Property. Affymax shall solely own all Patents and Know-How and other intellectual property based on the Drug Substance that does not relate solely to general peptide synthesis technology
("Project Intellectual Property"), and APC shall, and hereby does, assign to Affymax any and all of APC's right, title and interest in all Project Intellectual Property. 

        Each
party hereby grants the other party a non-exclusive, fully paid-up, worldwide license with unrestricted right to sublicense under such party's
Non-Project Intellectual Property that relates solely to the manufacture and use of Feasibility Drug Substance or Early-Stage Clinical Drug Substance and, in either case, is Controlled by
such party solely as may be necessary for the parties to perform their obligations under this Letter Agreement, including obligations to any current or future sublicensee(s). Affymax hereby grants to
APC a non-exclusive, fully paid-up, worldwide license under the Project Intellectual Property solely for APC to manufacture the Feasibility Drug Substance or Early-Stage
Clinical Drug Substance for Affymax pursuant to this Letter Agreement. 

5.    Work Plan. As soon as practicable after entering into this Letter Agreement, Affymax and APC shall mutually agree in writing on a
detailed work plan for the completion of the Feasibility Phase and Development Phase of the Project (the "Work Plan"). The Work Plan shall include without limitation scale-up, purification
and process development work to be carried out by APC through the Development Phase. 

6.    Project Team. As soon as practicable after entering into this Letter Agreement, Affymax and APC shall form a committee (the
"Project Team"), with each party designating two (2) members of the Project Team. The Project Team will be responsible for reviewing the progress of the Project under the Work Plan and to
discuss and decide on any potential revisions of the Work Plan. The Project Team may make decision only by the unanimous consensus of all members. Decisions of the Project Team must be in writing. If
the Project Team is unable to reach unanimous consensus on an issue, the final decision with respect to such issue shall be made by Affymax's Chief Operating Officer, however, after the BPR has been
approved and released by APC's Quality Assurance Department, issues principally related to the manufacturing facility general operations and specifically related to compliance with current Good
Manufacturing Practice (cGMP) for manufacture of Early-Stage Clinical Drug Substance shall be decided by APC's Chief Operating Officer. The Project Team shall have no authority to amend or waive
compliance with this Letter Agreement. 

7.    Facilities and Equipment. APC shall dedicate exclusively to the Project: (i) the manufacturing suite identified as Room 306 for
synthesis and Room 401 for purification; and (ii) the equipment at its facility at Vista, California. 

8.    Compliance with Laws; Change in Manufacturing Process. APC shall comply, and shall contractually require that its Affiliates comply,
with all applicable supranational, national or 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

local
laws, rules or regulations ("Applicable Laws") in discharging APC's development, supply and manufacturing obligations. APC shall obtain Affymax's prior written approval before implementing any
changes in the materials, equipment, process or procedures used to manufacture Drug Substance that would constitute a "major" change. A "major" change shall be any change that results in a change to a
regulatory filing for the. Drug Substance under Applicable Law. 

9.    Raw Materials Services; In-Process Testing. APC shall provide to Affymax, in accordance with the Work Plan and cGMP, all
ordering, testing, inventorying and releasing services for all raw materials used in the manufacture of the Drug Substance under this Letter Agreement. As part of the CMC Documentation, APC shall
document the source and testing of all starting materials and vendors/sources, amino acid derivatives and resins used, chemical reagents, solvents, and polyethylene glycol. 

10.    Delivery Terms. APC shall deliver all Feasibility Drug Substance and/or Early-Stage Clinical Drug Substance shipped via World Courier
or Fed Ex to Affymax, or its agent at Affymax's request. APC shall arrange for insurance and shipping of such Drug Substance at Affymax's reasonable expense. 

11.    Testing, Acceptance and Rejection. Upon Affymax's receipt of each batch of Early-Stage Clinical Drug Substance from APC, Affymax or its
designee shall have thirty (30) days (the "Testing Period") to inspect each such batch to determine its compliance with APC's warranties in Paragraph 14 of this Letter Agreement. By the
end of the Testing Period, Affymax shall notify APC in writing if Affymax accepts or rejects such batch based on such testing. If Affymax were to reject any batch of Early-Stage Clinical Drug
Substance, APC shall immediately commence production of a replacement fifty (50) gram batch if so instructed by Affymax in writing using best efforts to complete production and release the
replacement batch withyin six weeks of receiving Affymax's written instruction, and also shall promptly notify Affymax in writing if it either: (i) agrees with the rejection, in which event APC
shall request in writing that Affymax either return or destroy the rejected batch of Early-Stage Clinical Drug Substance (at no additional cost to Affymax); or (ii) dispute Affymax's rejection.
If APC disputes Affymax's rejection, the APC shall promptly provide Affymax with an equivalent amount of a replacement batch of Early-Stage Clinical Drug Substance (at no additional cost to Affymax),
and the parties shall engage a mutually acceptable, third party laboratory to make a final and binding determination if Affymax's rejection was proper. The fees and expenses of such laboratory testing
shall be borne entirely by the party against whom such findings are made. If such laboratory determines that such batch of Early-Stage Clinical Drug Substance is in compliance with the product
specifications or has not been reasonably rejected, then such batch shall automatically be deemed to have been accepted by Affymax, and Affymax will pay the amount for the batch of Early-Stage
Clinical Drug Substance initially rejected by Affymax, and any replacement Early-Stage Clinical Drug Substance provided by APC, in accordance with this Letter Agreement. If such laboratory determines
that such batch of Early-Stage Clinical Drug Substance has been reasonably rejected, or if APC agrees with Affymax's initial rejection, then APC shall, at Affymax's sole option, either promptly
replace the rejected batch of Early-Stage Clinical Drug Substance (at no additional cost to Affymax), if APC has not already done so per Affymax's written instruction to commence immediate production
of an additional fifty (50) gram batch upon notification of Affymax's rejection and undertaken best efforts to release and 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

ship
the additional fifty (50 gram batch within six weeks of receipt of said Affymax's written instruction, or refund Affymax for any amounts actually paid by Affymax for such rejected batch of
Early-Stage Clinical Drug Substance. 

12.    Access. As soon as practicable after entering into this Letter Agreement, Affymax shall have the right to place one or more Affymax
representatives at the APC manufacturing site upon reasonable prior notice and during regular business hours Affymax personnel shall have access to the area of the facility where the Drug Substance is
developed and manufactured (according to APC's standard operating procedures) as well as have access to copies of batch records and any other documentation relating to development and manufacture of
Product by APC under this Letter Agreement and shall be free to copy and use such documentation (except for batch records which may be inspected only on APC's premises) as reasonably required for any
normal regulatory or business use relating to Drug Substance. Notwithstanding the provisions of Section 4 (Intellectual Property; Licenses), Affymax agrees to keep all information related to
projects, trade secrets, business information, and all other information outside of the Affymax project confidential, whether acquired intentionally or unintentionally. 

13.    Audits. Affymax shall have the right to inspect APC's records relating to the development, supply and manufacture of Drug Substance no
more than once in any six (6) month period; provided, however, that Affymax may have-the right-to conduct additional inspections if such—additional
inspections are otherwise required under Applicable Laws or by applicable regulatory authorities. Affymax shall also have the right to conduct fmancial audits on financials related to development and
manufacturing of the Drug Substance no more than once in any twelve (12) month period. 

14.    Warranties. APC warrants and covenants that for any quantity of Feasibility Drug Substance or Early-Stage Clinical Drug Substance
delivered to Affymax: (i) APC shall manufacture such quantity in accordance with cGMP and Applicable Laws; (ii) the Feasibility Drug Substance supplied by APC to Affymax shall conform to
the Interim Specifications at the time of delivery; and (iii) the Early-Stage Clinical Drug Substance supplied by APC to Affymax shall conform to the Clinical Specifications, as on
Exhibit A pages 1 and 2 and further defined in Exhibit B at the time of delivery. 

15.    Confidentiality. Each party shall use commercially reasonable efforts to maintain all Confidential Information (defined below)
disclosed to it by the other party in trust and confidence and not disclose any such Confidential Information to any third party without the prior written consent of such other party. Furthermore,
each party covenants that it shall not use the Confidential Information of the other party except to perform its obligations under this letter Agreement. As used in this Letter Agreement,
"Confidential Information" shall mean all proprietary information of a party, and any tangible embodiments thereof, provided by or on behalf of such party to the other party either in connection
with the discussions and negotiations pertaining to this Letter Agreement or in the course of performing this Letter Agreement, except for any portion of such information or embodiment that, as
demonstrated by competent written proof: (i) is publicly disclosed by the disclosing party, either before or after it becomes known to the receiving party; (ii) was known to the
receiving party, without obligation to keep it confidential, prior to when it was received from the disclosing party; (iii) is subsequently disclosed to the receiving party by a third party
lawfully in possession thereof without obligation 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

to
keep it confidential; or (iv) has been publicly disclosed other than by the disclosing party and without breach of an obligation of confidentiality with respect thereto. 

16.    Term and Termination. The term of this agreement will commence upon the signing of this Letter Agreement and, unless and until
superceded by the definitive Development and Supply Agreement, shall expire on 28 February 2004. Affymax may terminate the agreement without penalty or further obligation to APC if any of the
following conditions occur: (i) APC has not produced and released the first batch or lot of Early-Stage Clinical Drug Substance meeting the Clinical Specifications from the Development Phase by
December 15, 2003 or (ii) APC has not met the performance milestones outlined in the Work Plan, including without limitation any delays by APC in providing Affymax with full cooperation
and compliance for Affymax to file the CMC package. 

        Affymax
may exercise its termination right under this Letter Agreement at any time the foregoing conditions in this Paragraph 16 arise by providing a written notice to APC, and
the effective date of such termination shall be three (3) months from date that Affymax provides such notice. In the event of such a termination, Affymax will pay APC for any Drug Substance -
ordered by Affymax during such three (3)-month period prior to termination in accordance with the forecasts provided by Affymax at a price equal to the then-current transfer price of Drug
Substance for the first two (2) quarters contained in the forecast preceding such termination, and such payment shall be made within 30 days following delivery of the ordered Drug
Substance. Affymax will also pay APC the total amount of any manufacturing-specific milestone payments that accrue during the three (3) months prior to the date such termination becomes
effective. 

17.    Yield Improvement. APC shall use commercially reasonable efforts to identify and target potential areas of yield improvement relating
to the performance of its obligations under this Letter Agreement
and the Development and Supply Agreement. APC shall pass all cost savings resulting from such yield improvement to Affymax through a reduced cost of goods for manufacturing and supplying the Drug
Substance. 

18.    General Terms. This Letter Agreement, and all Exhibits attached hereto and incorporated herein, embody the entire, final and complete
agreement and understanding between the parties and replace and supersede all prior discussions and agreements between them with respect to its subject matter. Any claim, dispute or controversy
relating to this Letter Agreement shall be governed under the laws of the State of California and any applicable Federal laws of the United States, without regard to any conflicts of laws provisions
that would require the application of laws other than those of California. Furthermore, the parties agree that the United Nations Convention on Contracts for the International Sale of Goods shall be
excluded from the application of governing law. If any provision of this Letter Agreement is found by a court of competent jurisdiction to be unenforceable, then such provision will be construed, to
the extent feasible, so as to render the provision enforceable, and if no feasible interpretation would save such provision, it will be severed from the remainder of this Letter Agreement. The
remainder of this Letter Agreement will remain in full force and effect, unless the severed provision is essential and material to the rights or benefits received by either party. In such event, the
parties will negotiate, in good faith, and substitute a valid and enforceable provision or agreement that most nearly implements the parties' intent in entering into this Letter Agreement. The failure
of a party in any one (1) or more instances to insist upon strict 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

performance
of any of the terms and conditions of this Agreement shall not constitute a waiver or relinquishment, to any extent, of the right to assert or rely upon any such terms or conditions on any
future occasion. 

19.    Affiliates. Each party may use Affiliates to perform such party's obligations under this Letter Agreement; provided, however, that such
party contractually binds such Affiliate to the terms and conditions of this Agreement and the original party guarantees the performance of its Affiliate. "Affiliate" shall mean any other party that,
directly or indirectly, through one (1) or more intermediaries, controls, is controlled by, or is under common control with such first party. For purposes of this definition only, "control"
and, with correlative meanings, the terms "controlled by" and "under common control with" shall mean: (i) the possession, directly or indirectly, of the power to direct the management or
policies of a party, whether through the ownership of voting securities or by contract relating to voting rights or corporate governance; or (ii) the ownership, directly or indirectly, of more
than fifty percent (50%) of the voting securities or other ownership interest of a party; provided
that, if local law restricts non-U.S. ownership, control will be established by direct or indirect ownership of the maximum ownership percentage that may, under such local law, be owned by
non-U.S. interests. 

20.    Development and Supply Agreement. This Letter Agreement is intended to be binding upon the parties; provided, however, that the parties
shall use commercially reasonable efforts to negotiate the definitive Development and Supply Agreement in good faith as soon as practicable after the execution of this Letter Agreement. The parties
expressly understand, however, that in the event the parties do not enter into the definitive Development and Supply Agreement, then the terms of this Letter Agreement shall control and continue to be
binding upon the parties. The definitive Development and Supply Agreement shall contain the provisions found in this Letter Agreement, as well as other provisions that are typically found in similar
commercial development and supply agreements, including without limitation: a detailed work plan for the scale-up and commercial manufacturing phases of the Drug Substance; forecasting and
ordering provisions; regulatory support rights; technology transfer provisions; second source rights; risk allocation and indemnification; insurance and risk allocation; and other terms typically
contained in agreements governing similar development and supply of similar products. In addition, the definitive Development and Supply Agreement will contain a provision for the parties to negotiate
in good faith a subsequent commercial supply agreement and the pricing basis thereunder. 

        To
confirm your understanding and acceptance of this Letter Agreement on behalf of APC, please sign and return to me the original of this Letter Agreement, keeping a copy of the signed
Letter Agreement for your records. 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

        We
look forward to continuing and expanding our productive relationship with APC. 

Best
regards, 

/s/
Arlene M. Morris 

Arlene
M. Morris

Chief Executive Officer 

Accepted
and agreed on behalf of APC and its Affiliates: 

	

By:	

/s/  SHAWN LEE      
	
 	

 
	Its.:	Chief Operating Officer
	 	 
	Date:	October 9, 2003
	 	 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

Exhibit A  

[Attach APC quote letter of 17 July 2003 identified as Quotation Number 031707-G2]

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

	Chris Holmes, Ph.D.

Senior Director

Affymax Research Institute

4001 Miranda Ave.

Palo Alto, CA 94304

(650) 812-8700 Phone

(650) 424-0832 Fax

chris_holmes@Affymax.com	 	July 17, 2003
	 	 	Quotation Number 031707-G2

Quotation expires in 30 days.

Dear
Dr. Holmes: 

        It
is my pleasure to provide you with the following proposal for the synthesis of your peptide conjugate manufactured under cGMP conditions. Please note that the quantity is in gross
weight. We can probably reduce the total lead time for delivery of the first 100g by 2-4 weeks by moving chemists down to Vista from Sunnyvale and working weekends and/or second shift. The
extra cost for us will be about $100,000 over ten weeks. The GMP release of the peptide prior to conjugation will take 1 week and is in the timeline calculation which we have not had time to refine as
yet. Please review the information and let me know if you have any questions. We will be available to discuss this with you next week at APS. 

A)    Prices:  

	Product

Number
 
	 	Sequence
	 	Purity By

HPLC
	 	Quantity

Gross
	 	Price

(US$)
	 	Delivery (wks)

	TBD	 	[*]	 	= or > [*]	 	100 g	*	[*]	 	[*]
	 	 	 	 	 	 	1kg	 	[*]	 	[*]
	 	 	 	 	 	 	5kg	 	[*]	 	[*]
	 	 	 	 	 	 	 	 	(est.)	 	 

*including
PEG Raw Materials Costs [*] 

B)    Specifications for GMP Release of Peptide:  

        [*]

C)    Specifications for GMP Release of Conjugate: TBD  

D)    Terms:  

	1.
	Under
the terms of this proposal, American Peptide Company (APC) is proposing to provide the customer with the product mentioned above. APC will prepare and provide this compound as
non-sterile lyophilized bulk. The manufacturing of this product will be performed under cGMP conditions. 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

	2.
	This
product will be labeled as; "Caution: New Drug Substance, for manufacturing, processing, or repackaging in the preparation of a new drug or new animal drug limited by Federal (or
United States) law to investigational use only, as required by 21 CRF 312.6(a)."

	3.
	APC
will purify the product with a dedicated HPLC column in a GMP-dedicated cleanroom.

	4.
	APC
warrants that the product meets the product specifications agreed to by and between APC and the customer, as determined by the analytical methods described in the product
specification section.

	5.
	APC
makes no warrantees direct or implied about the suitability of this product for any use by the customer. APC is not liable for any incidental, consequential or contingent damages
arising from any use of this product.

	6.
	APC
can provide the appropriate documentation that may be required for preparing regulatory product submissions, such as IND's, upon request. The cost for preparation and delivery of
documentation is not included in the cost of the delivery of the product.

	7.
	Terms:
Our terms are net 30 days (upon credit check), FOB Sunnyvale or Vista, California USA. Shipping, handling & insurance charges will be added to the invoice. 

Sincerely
Yours, 

Jim
Hampton

VP Business Development

American Peptide Company

777 Evelyn Ave.

Sunnyvale, CA 94086

Ph 800/926-8272 x-114

Fax 408/733-9057

jhampton©americanpeptide.com 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

Exhibit B  

Product  

	Product

Number
 
	 	Sequence
	 	Purity By

HPLC
	 	Quantity

Gross
	 	Price

(US$)
	 	Delivery (wks)

	322662	 	[*]	 	= or > [*]	 	100 g	 	[*]	 	[*]

Specifications for Release [*] Intermediate:  

	Attribute
 
	 	Specifications
	 	Test Methods

	[*]	 	[*]	 	[*]

Specifications for GMP Release [*]:  

	Attribute
 
	 	Specifications
	 	Test Methods

	[*]	 	[*]	 	[*]

Additional Specifications for [*] for Information Only:  

	Attribute
 
	 	Specifications
	 	Test Methods
	 	Cost

	[*]	 	[*]	 	[*]	 	[*]

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00107-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00107-of-00352.parquet"}]]